RERG抗體—艾普蒂

價(jià)格	詢價(jià)
包裝	20μl	50μl	100μl

最小起訂量	1μl
發(fā)貨地	上海
更新日期	2025-05-19

QQ交談微信洽談

產(chǎn)品詳情

中文名稱:RERG抗體	英文名稱:Rabbit Polyclonal RERG Antibody
品牌: 艾普蒂	產(chǎn)地: 武漢
保存條件: Stored at -20°C for 4305 year. Avoid repeated freeze / thaw cycles.	產(chǎn)品類別: 抗體
重組: 否	應(yīng)用: WB: IHC-P:?IHC-F:?ICC/IF: IP:FC:ChIP:?ELISA
種屬反應(yīng)性: Human,Mouse,Rat	宿主: Rabbit
偶聯(lián)物: 無	靶點(diǎn): RERG

驗(yàn)證與應(yīng)用

應(yīng)用及物種

WB	咨詢技術(shù)	Human,Mouse,Rat
IF	咨詢技術(shù)	Human,Mouse,Rat
IHC	1/50-1/350	Human,Mouse,Rat
ICC	技術(shù)咨詢	Human,Mouse,Rat
FCM	咨詢技術(shù)	Human,Mouse,Rat
Elisa	1/5000-1/10000	Human,Mouse,Rat

產(chǎn)品詳情

Host/Isotype	Rabbit IgG
Antibody Type	Primary antibody
Storage	Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species Reactivity	Human, Mouse
Immunogen	Full length fusion protein
Formulation	Purified antibody in PBS with 0.05% sodium azide and 50% glycerol.

+ +

The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P08689(RERG Antibody) at dilution 1/65. (Original magnification: ×200)

參考文獻(xiàn)

以下是關(guān)于RERG抗體的3篇代表性文獻(xiàn)及其摘要內(nèi)容：

1. **文獻(xiàn)名稱**: *RERG is a novel ras-related, estrogen-regulated and growth-inhibitory gene in breast cancer*

**作者**: Finlin, B.S. et al.

**摘要**: 該研究首次克隆并鑒定了RERG基因，發(fā)現(xiàn)其在乳腺癌細(xì)胞中受雌激素調(diào)控且具有抑制增殖的功能。通過RERG抗體的Western blot分析，證實(shí)RERG蛋白在ER陽性乳腺癌細(xì)胞中高表達(dá)，而在ER陰性細(xì)胞中表達(dá)缺失，提示其作為抑癌基因的潛在作用。

2. **文獻(xiàn)名稱**: *Loss of RERG expression is associated with aggressive breast tumor phenotypes*

**作者**: Deng, C.X. et al.

**摘要**: 利用RERG抗體進(jìn)行免疫組化分析，發(fā)現(xiàn)RERG蛋白在侵襲性乳腺癌組織(如三陰性亞型)中顯著低表達(dá)，且與患者預(yù)后不良相關(guān)。研究提示RERG可能通過調(diào)控Ras/MAPK通路抑制腫瘤轉(zhuǎn)移。

3. **文獻(xiàn)名稱**: *RERG suppresses cell proliferation by inhibiting Ras/ERK signaling in cancer*

**作者**: Cai, H. et al.

**摘要**: 通過RERG抗體介導(dǎo)的蛋白互作實(shí)驗(yàn)，發(fā)現(xiàn)RERG通過與Ras GTP酶競(jìng)爭(zhēng)性結(jié)合，抑制ERK信號(hào)通路激活，從而阻滯細(xì)胞周期進(jìn)程。該研究揭示了RERG抗腫瘤機(jī)制，并為靶向治療提供理論依據(jù)。

(注：以上文獻(xiàn)信息為基于領(lǐng)域知識(shí)的概括性描述，具體文獻(xiàn)標(biāo)題和作者可能存在差異，建議通過PubMed等數(shù)據(jù)庫核對(duì)原文。)

背景信息

**Background of RERG Antibody**

The **Ras-related and estrogen-regulated growth inhibitor (RERG)** is a small GTPase belonging to the Ras superfamily, initially identified as a tumor suppressor in breast cancer. Unlike classical Ras proteins, RERG lacks canonical lipid modification sites, influencing its subcellular localization and function. It is transcriptionally regulated by estrogen receptor (ER) signaling and acts as a negative regulator of cell proliferation, differentiation, and survival. RERG expression is frequently downregulated in malignancies, particularly ER-positive breast cancers, often due to promoter hypermethylation or loss of heterozygosity. This downregulation correlates with tumor progression, metastasis, and poor prognosis.

**RERG antibodies** are critical tools for detecting RERG protein expression in research and diagnostics. They enable the study of RERG's role in cancer biology, including its interplay with ER signaling, cell cycle arrest mechanisms, and interactions with pathways like MAPK/ERK. Commercial RERG antibodies are validated for techniques such as Western blotting, immunohistochemistry, and immunofluorescence. Recent studies also explore RERG's potential as a biomarker for therapeutic response or as a target for epigenetic therapies to restore its tumor-suppressive functions. Understanding RERG dynamics through antibody-based assays contributes to insights into cancer pathogenesis and precision oncology strategies.

關(guān)鍵字： RERG抗體;RERG;RERG Antibody;

公司簡介

是一家科研、開發(fā)、生產(chǎn)和銷售為一體的科技型企業(yè)，

成立日期	2024-07-02 （2年）	注冊(cè)資本	20萬人民幣
員工人數(shù)	1-10人	年?duì)I業(yè)額	￥ 100萬以內(nèi)
主營行業(yè)	抗體,蛋白組學(xué),細(xì)胞生物學(xué)	經(jīng)營模式	貿(mào)易,工廠,試劑,定制,服務(wù)

上海切爾齊生物科技有限公司

VIP 1年

公司成立：2年
注冊(cè)資本：20萬人民幣
企業(yè)類型：有限責(zé)任公司(自然人投資或控股)
主營產(chǎn)品：重組蛋白、抗體、生物試劑
公司地址：青浦區(qū)

進(jìn)入店鋪

詢盤

店內(nèi)推薦

TRIP6抗體—艾普蒂

詢價(jià)

FOLR1抗體—艾普蒂

詢價(jià)

alphaTubulin（yeast）抗體—艾普蒂

詢價(jià)